Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Yoshiko Asaka-Amano"'
Autor:
Katsushi Kurosu, Yuichi Takiguchi, Yuji Tada, Yoshiko Asaka-Amano, Tatsuo Kawashima, Keiichi Nagao, T Moriya, Takayuki Kuriyama
Publikováno v:
Lung Cancer. 58:253-259
Even with the standard first-line chemotherapy, advanced non-small cell lung cancer (NSCLC) recurs in most cases. The purpose of this study is to develop a new chemotherapeutic regimen for patients with NSCLC that has relapsed or was refractory to pr
Autor:
Sayaka Onoda, Takayuki Kuriyama, Akira Yokoyama, Akihiro Tagawa, Noriyuki Masuda, Koshiro Watanabe, Masao Harada, Hiroaki Okamoto, Takashi Ogura, Nobuhiko Seki, Yoshiko Asaka-Amano, Kazutsugu Uematsu, Kenji Eguchi, Hiroshi Kunikane, Hiroshi Isobe, Yumi Kuroiwa, Takashi Seto, Masanori Yokoba, Yuichi Takiguchi
Publikováno v:
Journal of Clinical Oncology. 24:5448-5453
Purpose This multicenter, phase II study was conducted to evaluate the activity of amrubicin, a topoisomerase II inhibitor, against refractory or relapsed small-cell lung cancer (SCLC). Patients and Methods SCLC patients with measurable disease who h
Autor:
Reiko Uruma, Takayuki Kuriyama, Yuichi Takiguchi, Yoshiko Asaka-Amano, Takashi Uno, Nobuhiro Tanabe, Hisao Itoh, Koichiro Tatsumi, Yasunori Kasahara, Katsushi Kurosu
Publikováno v:
International Journal of Clinical Oncology. 10:418-424
Irinotecan, when combined with cisplatin, is an effective treatment for advanced non-small cell lung cancer (NSCLC). This constitutes a rationale for conducting a phase I study of chemoradiotherapy including this combination for locally advanced NSCL
Autor:
Mari, Yatomi, Yuichi, Takiguchi, Yoshiko, Asaka-Amano, Makoto, Arai, Yuji, Tada, Katsushi, Kurosu, Seiichiro, Sakao, Yasunori, Kasahara, Nobuhiro, Tanabe, Koichiro, Tatsumi, Naohiko, Seki, Takayuki, Kuriyama
Publikováno v:
Anticancer research. 27(5A)
Substantial evidence has disclosed that some cytotoxic agents have complex activities in influencing signal transduction pathways in cells.cDNA microarray analysis was performed after exposing a human squamous cell carcinoma cell line, RERF-LC-AI, to
Autor:
Nobuhiro Tanabe, Mari Yatomi, Yoshiko Asaka-Amano, Koichiro Tatsumi, Katsushi Kurosu, Takayuki Kuriyama, Yasunori Kasahara, Yuichi Takiguchi
Publikováno v:
Radiation research. 167(6)
This study was designed to determine the effects of the treatment schedule on the interaction between cisplatin and radiation. Cells of a human squamous cell lung cancer cell line were treated with cisplatin and radiation using three treatment protoc
Autor:
Reiko Watanabe-Uruma, Yuichi Takiguchi, Masato Shingyoji, Koichiro Tatsumi, Yoshiko Asaka-Amano, Hiroshi Matsubara, Nobuhiro Tanabe, Takayuki Kuriyama, Katsushi Kurosu, Yasunori Kasahara
Publikováno v:
Cancer science. 95(6)
Irinotecan is an active cytotoxic agent for various cancers, and is converted to SN-38, its most active metabolite, by carboxylesterase converting enzyme (CCE) in vivo. Although the primary metabolic site is in the liver, ex vivo studies have proven
Autor:
Kurosu K, T. Kawashima, Takayuki Kuriyama, T Moriya, Keiichi Nagao, A. Mizoo, Yasuo Takiguchi, Yoshiko Asaka-Amano
Publikováno v:
Journal of Clinical Oncology. 24:17002-17002
17002 Background: A current option for recurrent NSCLC is monotherapy with docetaxel. However, cisplatin, if tolerable, may still have power for this condition. Irinotecan is also a key drug for NSCLC. The objectives of this study were to evaluate th